Biotech isn’t for the faint of heart. It’s an industry where the stakes are life and death, and the hardest challenges—those #undruggableproteins — have loomed large as unscalable peaks. General Proximity isn’t here to admire the view; they’re dismantling the mountain, one molecule at a time.
Fresh off a $16 million seed round led by Felicis, with backing from Y Combinator, Modi Ventures, and Wilson Sonsini Goodrich & Rosati, General Proximity is proving that the real magic in biotech happens in the margins. CEO Armand Cognetta III, PhD—a name well-known in the corridors of Scripps Research has built something that doesn’t just inch the industry forward. It vaults it into a future where proximity isn’t just the company’s name; it’s their philosophy.
At the heart of it all is their OmniTAC platform, a proprietary approach that takes aim at proteins the rest of the field has left for dead. The ones too tricky, too complex, or too far out of reach. OmniTAC doesn’t just close the gap—it annihilates it, enabling precise, selective modifications that turn “undruggable” into yesterday’s problem.
Why does this matter? Time. Money. Lives. Cutting #drugdiscovery timelines by 40% isn’t just a flex; it’s an industry earthquake. #Oncology, #neurodegenerativediseases, #cardiometabolicconditions, and #longevity are all squarely in their sights, and if you think that sounds ambitious, you’re right. But when your team’s résumé includes over 200 clinical programs and 36 FDA-approved drugs, ambition is the baseline.
The biotech industry is staring down a $2.4 trillion market by 2028, and General Proximity isn’t just positioned to ride that wave—they’re shaping the currents. What’s most striking is how their technology empowers the smaller players, giving midsize firms a chance to punch well above their weight in a landscape dominated by #BigPharma's checkbook.
This funding round isn’t just capital; it’s a signal. A signal that precision-driven platforms like General Proximity’s are more than a promising idea—they’re the infrastructure of biotech’s future. The more we shrink the distance between #undruggable and treatable, the closer we get to an industry where no disease gets the luxury of being out of reach.
Proximity, in biotech and in life, changes everything. And with General Proximity leading the charge, the distance between what’s possible and what’s next has never been shorter.
#Startups #StartupFunding #BioTech #Healthcare #HealthTech #Technology #Innovation #Disruption #PatientCare #PatientTech #TechEcosystem #StartupEcosystem
